1. Introduction {#sec1-ijms-21-01951}
===============

In the past decade, it has become clear that the behavior of a malignant tumor is related not only to the malignant cell itself, but also to the properties of the stromal microenvironment of the tumor \[[@B1-ijms-21-01951],[@B2-ijms-21-01951]\]. In particular, in tumors of epithelial origin (i.e., carcinomas), the stroma appears to play an important role in the invasive properties of the tumor, its capacity to form metastasis as well as its evolution and prognosis \[[@B3-ijms-21-01951]\].

The stroma of carcinomas is very complex concerning extracellular matrix (ECM) and cellular elements that contribute to tumor development. The most relevant cellular component of the tumor stroma are activated fibroblasts, characterized by an increased expression of α-smooth muscle actin (αSMA) and vimentin, a change from the fusiform to stellate shape, and enhanced ECM production \[[@B4-ijms-21-01951]\]. They also alter the repertoire of paracrine signals including those related with immunoregulation \[[@B5-ijms-21-01951]\]. These alterations appear to be the result of epigenetic changes that make these newly acquired properties irreversible. These altered fibroblasts, known as CAFs are somewhat similar to fibroblast present in cases of fibrosis, such as recessive dystrophic epidermolysis bullosa (RDEB) \[[@B6-ijms-21-01951],[@B7-ijms-21-01951]\]. In addition to activated fibroblasts, the stroma of tumors displays a newly formed vascular network, which is recognized as essential in tumor development and metastatic behavior \[[@B8-ijms-21-01951]\]. More recently, the focus of many laboratories has shifted to investigate the possible role of the ECM in cancer development and to the concomitant role of tumor fibroblasts to the synthesis and maintenance of this specific pro-tumorigenic ECM \[[@B6-ijms-21-01951],[@B7-ijms-21-01951]\].

We have recently characterized a genetic signature of the CAF-like fibroblasts derived from three unrelated genodermatosis prone to develop cancer \[[@B9-ijms-21-01951]\], stressing once more the importance of these cells in creating the proper environment, which contribute to the uncontrolled growth of transformed cells. However, despite the importance of in vitro experiments like ours and others, the actual growth of epithelial tumors and the contribution of the tumorigenic stroma are not always easy to recapitulate in xenografts. In this regard, the cancer experiments carried out in rodents, critical not only in the study of the mechanisms of carcinogenesis but also as an essential tool in the development of treatments, has a major deficiency. The original stroma of the tumor becomes replaced by stroma of the murine host leading to important changes in tumor behavior \[[@B10-ijms-21-01951],[@B11-ijms-21-01951],[@B12-ijms-21-01951]\]. This is probably one of the major causes of disagreement between results in animal experiments and those achieved in clinical trials. In some cases, the stroma developed by the host is even unable to support the growth of epithelial tumors or cell lines derived from them, and therefore it is difficult to develop appropriate xenograft tumor models in some forms of cancer \[[@B6-ijms-21-01951]\].

In this paper, we describe our efforts to humanize tumor stroma in an animal model, by tissue engineering techniques, with the goal of achieving tumors xenografts that mimics the actual behavior of human SCCs.

2. Results {#sec2-ijms-21-01951}
==========

In order to provide a pro-tumorigenic humanized stroma to facilitate the growth of the SCC, we used two different approaches ([Figure 1](#ijms-21-01951-f001){ref-type="fig"}). In protocol 1 we use the simultaneous injection of tumoral and stromal cells embedded in a compatible biomaterial. Whereas in protocol 2, the generation of the humanized stroma was performed before the injection of the neoplastic cells.

In contrast, injection of cells according to protocols 1 and 2, led to tumor growth as evidenced by macroscopic visualization and fluorescence imaging ([Figure 2](#ijms-21-01951-f002){ref-type="fig"} and [Figure 3](#ijms-21-01951-f003){ref-type="fig"}).

The efficiency of transfection of both cell types was evaluated during the in vitro cell culture of the graft in protocol 1, before implantation, by fluorescence images ([Figure 3](#ijms-21-01951-f003){ref-type="fig"}a) and the persistence of humanized stroma was observed after 8-weeks tumors was evaluated by the presence of green fluorescent cells macroscopically within the tumor mass in the flank of the mouse ([Figure 3](#ijms-21-01951-f003){ref-type="fig"}b). While the 3D macroscopic image showed that the stroma appeared to surround the tumor mass, the microscopic results showed that fibroblasts were intermingled with nests of tumor cells. Green (GFP) and red (RFP) fluorescence could be observed following both protocols. These results were confirmed by immunochemical staining of human specific vimentin in sections of the tumors as shown below ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}c,g).

Histological Characterization of the Bioengineered Tumor Stroma
---------------------------------------------------------------

A histopathological characterization was performed in all the tumors that were developed by protocol 1 in immunodeficient mice, these were characterized as well-differentiated SCC ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}a) with a rich collagenous stroma ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}b) and a noticeable residual presence of the artificial matrix. Despite the fact that the stroma in protocol 1 exhibited signs of survival and functionality, in some of the tumors, the epithelial cell tumor nests, were small and did not show significant proliferative activity ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}d).

In contrast, in the case of tumors (also well-differentiated SCC) developed using protocol 2 ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}e--h) a clear increase in proliferative nests, as determined by Ki67 staining, was observed ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}h), and the quantification of the epithelial part of the tumors showed an increase of Ki67+ cells, in the case of tumors developed by protocol 2 ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}i). In fact, tumor architecture was much more similar to that observed in patient tumor biopsies (data not shown). The stroma, rich in thick and mature collagen fibers, intermixed with the tumor nests and surrounded the whole structure in a capsule-like arrangement ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}f). To confirm that human CAF-like cells have not been replaced by murine fibroblast, we performed immunohistochemistry staining of tumor sections using a human-specific vimentin antibody ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}c,g). Human vimentin positive fibroblasts, together with collagen-rich ECM, appear as the main components of the stroma surrounding the SCC cells nests.

3. Discussion {#sec3-ijms-21-01951}
=============

The lack of SCC models with a humanized stroma represents an important drawback hampering and delaying the development of effective therapies of this common cancer \[[@B10-ijms-21-01951],[@B11-ijms-21-01951],[@B12-ijms-21-01951],[@B16-ijms-21-01951]\]. In this regard, our study aimed to establish an experimental method that focused on the generation of a bioengineered stroma, capable of persisting and sustaining SCC growth. The importance of conditioning the environment for the successful growing of human carcinomas in immunodeficient mice is a very well-known phenomenon \[[@B18-ijms-21-01951],[@B19-ijms-21-01951],[@B20-ijms-21-01951]\]. One of the early observations regarding this issue comes from studies with prostate carcinoma cells LNCaP, which under normal conditions, do not grow in vivo, unless the site of injection is preconditioned by implantation of matrigel or coinjection with human fibroblasts. Interestingly and pertinent to our work is the fact that not all fibroblasts have the capacity to facilitate the growth of LNCaP cells. In fact, normal dermal fibroblasts have no effect while fibroblasts obtained from prostate tumors were more efficient \[[@B21-ijms-21-01951],[@B22-ijms-21-01951]\]. Models with other cell lines have also shown that stromal components may be required to grow or may accelerate the development of tumors such as breast cancer and non-small cell lung carcinomas \[[@B1-ijms-21-01951],[@B23-ijms-21-01951],[@B24-ijms-21-01951],[@B25-ijms-21-01951]\].

In the case of skin SCC, a humanized stroma not only facilitates tumor growth, but also allows the manifestation of its full aggressiveness. In fact, one of the chief issues related with the skin SCC is the unusual behavior with regards to their metastatic potential. In the skin, more than 90% of SCC are relatively indolent and very rarely cause metastasis. However, around 5--10% of skin SCC tumors are extremely aggressive such as those from the oral mucosa, head and neck, esophagus, lung etc. Many of the aggressive SCC of the skin develops in areas with chronic ulcers as in hereditary conditions like epidermolysis bullosa \[[@B13-ijms-21-01951],[@B14-ijms-21-01951],[@B26-ijms-21-01951]\]. The reason for this different behavior is still a subject of controversy and collaborative studies have recently shed light onto the matter \[[@B9-ijms-21-01951],[@B17-ijms-21-01951],[@B27-ijms-21-01951],[@B28-ijms-21-01951],[@B29-ijms-21-01951]\]. Recently, attention has been focused on a possible role of the stroma. In this regard, the murine model appears to be not very useful because the stroma of transplanted tumors, including PDX models, is rapidly replaced by the host \[[@B10-ijms-21-01951]\].

To cope with these methodological problems, two different strategies, adapted from previous approaches \[[@B10-ijms-21-01951]\], have been used here to develop in vivo xenograft SCC organotypic models. In our attempt to generate a new model we took advantage of two SCC cell lines derived from patients with RDEB. Despite the aggressive nature of the primary tumors giving rise to the cell lines employed, the lack of a pre-conditioning of the stroma (i.e., cancer-prone humanized stroma) prevented tumor development. However, as previously found in human breast cancer and prostate tumor modeling \[[@B30-ijms-21-01951]\], the pre-humanization and previous vascularization of the stroma seemed to be the most successful approach in SCC xenografting. In our case, the promotion of a vascularized bed prior SCC cells implantation showed a significant enhancement of tumor growth ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}e--h). In contrast, when the SCC constructs were transplanted all together (cancer cells with stromal cells), tumor growth was not very efficient ([Figure 4](#ijms-21-01951-f004){ref-type="fig"}a--d).

In addition to the aggressive nature of the tumor cells itself, these evidences underscore the critical importance of the previous existence of a well-established human and vascularized niche able to recapitulate tumor complexity.

Bioengineering tools allow modifying the different components of a particular tumor helping to understand their influence on tumor aggressiveness. In this regard, and taking into account the immune component of the tumors and the activation of specific T-cell populations that has been described for other tumors such as ovarian cancer \[[@B31-ijms-21-01951],[@B32-ijms-21-01951]\], the use of cancer and stromal cells from the same donors will be more appropriate than a heterologous system, as it has been described for aggressive tumors, such as neuroblastoma or pancreatic cancer \[[@B33-ijms-21-01951],[@B34-ijms-21-01951],[@B35-ijms-21-01951]\]. In any case, the flexibility of our model allows the combination of different cell populations and genetic backgrounds and facilitates the study of the role of each component in the aggressiveness of the tumor.

Taken together our proof-of-concept study shows that tissue engineering tools applied to modeling the complexity of tumor environment, emerge as a powerful and promising technology, also in the context of personalized medicine, where the prognosis of each tumor can differ according to the underlying pathology, such as bullous diseases.

4. Materials and Methods {#sec4-ijms-21-01951}
========================

4.1. Cell Culture {#sec4dot1-ijms-21-01951}
-----------------

CAF-like fibroblasts were obtained from biopsies of RDEB patients remnants of diagnosis donated for research under informed consent, after approval by the Ethics Committee of the University Hospital La Paz (Madrid, Spain) (approved date: 11 December 2018, approved number: HULP:PI-3426).

The SCC-keratinocyte cell lines (EB4 and EB106) were kindly provided by Dr. Andrew P. South, Department of Dermatology & Cutaneous Biology (Thomas Jefferson University, Philadelphia, PA, USA) \[[@B36-ijms-21-01951],[@B37-ijms-21-01951]\]. Both cell lines are RDEB-SCC derived, the EB4 line corresponds to the one with less tumorigenic potential while the EB106 cell line shows the most cancer-prone potential \[[@B38-ijms-21-01951]\]. Cells were cultured in DMEM medium (GIBCO-BRL, Gaithersburg, MD, USA) 10% FBS, (Hyclone™ GE Healthcare Life Science, Chicago, IL, USA) and antibiotic-antimycotic, (E3473N; Thermo Fisher, Waltham, MA, USA), following standard protocols, and once embedded in a biocompatible matrix; the medium was replaced by DMEM medium with 10% FBS and 50 μg/mlascorbic acid (Sigma, St Louis, MO, USA).

4.2. Retroviral Gene Transfer {#sec4dot2-ijms-21-01951}
-----------------------------

Human primary fibroblast (CAF-like cells) and keratinocyte cell line EB106 were transduced by incubation with a recombinant EGFP or RFP (tdTomato-expressing LZR-based, Clontech Laboratories, Inc. A Takara Bio Company, Mountain View, CA, USA) amphotropic retrovirus generated by transient transfection in 293T cells, as described in \[[@B39-ijms-21-01951],[@B40-ijms-21-01951]\]. Transduction was performed at a titer of 1 × 10^6^ to 5 × 10^6^ CFU/mL together with Polybrene (8 mg/mL) for 6 h on two consecutive days. After the second infection, the cells were given fresh medium and allowed to reach 80--90% confluence. Cells were then trypsin-detached, resuspended in phosphate-buffered saline (PBS) 2% FBS, analyzed for EGFP or RFP expression, and sorted by fluorescence-activated cell sorting (FACS) on a FACStar PLUS flow cytometer (Becton Dickinson, San Jose, CA, USA).

4.3. Tissue Engineering for Modeling Cutaneous SCC {#sec4dot3-ijms-21-01951}
--------------------------------------------------

The protocol proposed by Patel et al. \[[@B10-ijms-21-01951]\] was modified ([Figure 1](#ijms-21-01951-f001){ref-type="fig"}: Protocol 1 and Protocol 2) in order to optimize the period of time that is required for the development of the humanized ECM and minimize the number of cells used in the experiment.

Bioengineered scaffold was a combination of a biocompatible material (Spongostan Stand 50 × 70 × 10^2^ stuk, Johnson & Johnson Medical) and our fibrin gel, as previously described \[[@B41-ijms-21-01951]\]. A mixture containing RDEB-CAFs (1.5 × 10^5^ /gel) was prepared with 350 μL of seeding medium (DMEM + 10% FBS), 1.5 μL of ascorbic acid (50 μg/mL), 7.5 μL of antifibrinolytic (Amchafibrin® 500mg; Fides Ecopharma S.A), 100 μL of fibrinogen from plasma cryoprecipitate of pig blood, and 50 μL of bovine thrombin (Sigma) diluted in CaCl~2~ (25 mM).The mixture was placed in one well of 24-cell culture plates (Costar®; Corning, New York, NY, USA), covering 1 cm^2^ of Spongostan™, and allowed to solidify in an incubator. After gelification (1 h), 1 mL of seeding medium with ascorbic acid was added and replaced every 48 h.

Cutaneous tumors were developed by using tissue engineering techniques, combining cells, scaffolds, and transplantation procedures following two different experimental protocols described as followed and schematized in [Figure 1](#ijms-21-01951-f001){ref-type="fig"}.

### 4.3.1. Protocol 1: Simultaneous Implantation of Tumor Cells and Stroma {#sec4dot3dot1-ijms-21-01951}

It involves the simultaneous implantation of the stroma and the tumor cells (RDEB-CAFs and EB106 cancer keratinocytes) into the immunodeficient mice.

Three days post-ECM preparation, SCC-keratinocytes (1 × 10^6^ in 100 μL of seeding medium) were cultured in vitro inside the biocompatible scaffold through an injection. The external medium outside the biocompatible matrix-embedded was aspired prior to the incorporation of keratinocytes to prevent their suspension in the external media. The constructs were incubated for 1 h at 37 °C before 1 mL of seeding medium was added. Then, the organotypic tumors were cultured until transplantation into immunodeficient mice.

### 4.3.2. Protocol 2: Previous Establishment of the Stroma and Posterior Introduction of Tumor Keratinocytes {#sec4dot3dot2-ijms-21-01951}

The initial protocol was modified to develop a well-established and vascularized niche, previously to the implantation of cancer-prone keratinocytes (EB106) in order to enhance tumor growth and engraftment. Five days after ECM generation, the constructs were transplanted into immunodeficient mice and, once the pro-tumorigenic vascularized niche was developed (2 weeks post-transplantation of the construct), the SCC keratinocytes were incorporated.

In both protocols, 8 weeks post-transplantation, the mouse was euthanized, and the tumor tissue was dissected and submitted to the histology laboratory for embedding and sectioning.

4.4. Animals {#sec4dot4-ijms-21-01951}
------------

For the grafting protocol immunodeficient Rj: NMRI-Foxn1nu (NMRI nu) female mice (6 weeks old) were used (Elevage Janvier, France). Mice were aseptically cleansed and grafted. They were housed for the duration of the experiment at the CIEMAT Laboratory Animal Facility (European Registration number ES280790000183; approved date: 17 April 2012) in pathogen-free conditions. All experimental procedures were carried out according to the European and Spanish laws. All procedures were approved by the Institutional Animal Care and Use Committee according to all legal regulations, and biosafety and bioethics guidelines. During the experiments, a minimum number of *n* = 3 animals were studied for each condition described in the results section.

4.5. Histological Characterization of Regenerated Bioengineered Tumors {#sec4dot5-ijms-21-01951}
----------------------------------------------------------------------

Formalin-fixed paraffin sections (4--6 μm) were used for standard histological and IHC analyses. To determine tissue architecture, sections were stained with hematoxylin and eosin (Gill 2 Hematoxylin and Eosin Y alcoholic; Thermo Shandon, Altrincham, UK) following a standard Masson trichrome (Sigma-Aldrich kit) staining protocol. Immunohistochemistry was carried out using an anti-Ki-67 rabbit monoclonal antibody (Neomarkers clone SP6) for cell proliferation and human specific anti-vimentin antibody (Biogenex \#AM074-10M, USA) following the manufacturer's protocol. Specific biotinylated secondary antibodies (Jackson ImmunoResearch Laboratories; West Grove, PA, USA) were used and immunoperoxidase staining (Vectastain ABC kit; Vector Laboratories Inc., Burlingame, CA, USA) was performed using standard procedures. Sections were counterstained with hematoxylin and dehydrated in water solution containing increasing percentages of ethanol. Finally, the slides were placed 15 min in histoclear (National diagnostic, Atlanta, GA, USA) and mounted. Images were taken using an Olympus Bx41 microscope and digital camera.
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![Tissue engineering humanized stroma for development of squamous cell carcinomas (SCC) in immunodeficient mice: two different approaches were followed. In protocol 1 simultaneous injection of tumoral cells and stroma (cancer associated fibroblasts (CAF)-like cells and biocompatible matrix) was performed, whereas in protocol 2 the generation of a humanized stroma was performed 2 weeks before the injection of the neoplastic keratinocytes. SCC-cells and stromal fibroblasts derived from recessive dystrophic epidermolysis bullosa (RDEB) patients were used during this experimentation, given their high predisposition of RDEB patients to develop very aggressive SCC. Moreover, the similarities of the molecular profile between RDEB dermal cells with that of CAFs, which promotes the invasion of tumor cells, has been widely studied \[[@B6-ijms-21-01951],[@B13-ijms-21-01951],[@B14-ijms-21-01951],[@B15-ijms-21-01951],[@B16-ijms-21-01951],[@B17-ijms-21-01951]\]. In the first approach, to assess the tumorigenic potential of the SCC-derived cell lines used, immunodeficient mice were injected with tumor keratinocytes (EB4 or EB106), without the addition of exogenous stroma (2 × 10^6^ cells/animal. *n* = 3 in each experimental group). No tumor was detected after 60 days post-injection.](ijms-21-01951-g001){#ijms-21-01951-f001}

![Macroscopic characterization of tumors developed in the presence of humanized stroma after 8 weeks of transplantation. (**a**) Tumor developed by protocol 1; (**b**) tumor developed by protocol2.](ijms-21-01951-g002){#ijms-21-01951-f002}

![Persistence of tumor stromal cells in bioengineered SCC following protocols 1 and 2, respectively. (**a**) In vitro fluorescence microscope image from the cell culture, before transplantation, where both the EGFP-CAFs and RFP-SCC-keratinocytes are observed; scale bar: 200 μm. (**b**) In vivo3D fluorescence image obtained from the tumor, 8 weeks after implantation, using XLView Loupe. Scale bar: 2 mm.](ijms-21-01951-g003){#ijms-21-01951-f003}

![Histopathological analysis of representative tumors generated by different protocols of SCC stroma humanization. (**a--d**) Protocol 1; (**e--h**) protocol 2; (**a**) and (**e**)hematoxylin-eosin staining shows the structure of the tumors developed, as evidenced by the presence of tumor nests and cornified pearls and blood vessels in protocol 2; (**b**) and (**f**) Mason trichrome staining shows the different humanized tumoral stroma in both protocols;(**c**) and (**g**) show the human origin of fibroblasts surrounding the tumor structure by a h-vimentin staining; (**d**) and (**h**)show that tumors developed by protocol 2 have more proliferative cells as shown by a Ki67 staining.(**i**) Shows a quantification of the epithelial component of the tumor where ki67^+^ nuclei/100 epithelial cells is shown. For this calculation a total number of ten representative fields were included. Images are representative results for each group (*n* = 3). Scale bars 200 μm.](ijms-21-01951-g004){#ijms-21-01951-f004}
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